1. Home
  2. TLSI vs HCAI Comparison

TLSI vs HCAI Comparison

Compare TLSI & HCAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSI
  • HCAI
  • Stock Information
  • Founded
  • TLSI 2010
  • HCAI 2004
  • Country
  • TLSI United States
  • HCAI China
  • Employees
  • TLSI N/A
  • HCAI N/A
  • Industry
  • TLSI Medical Specialities
  • HCAI Miscellaneous manufacturing industries
  • Sector
  • TLSI Health Care
  • HCAI Consumer Discretionary
  • Exchange
  • TLSI Nasdaq
  • HCAI Nasdaq
  • Market Cap
  • TLSI 160.4M
  • HCAI 272.6M
  • IPO Year
  • TLSI N/A
  • HCAI 2025
  • Fundamental
  • Price
  • TLSI $5.19
  • HCAI $7.61
  • Analyst Decision
  • TLSI Strong Buy
  • HCAI
  • Analyst Count
  • TLSI 6
  • HCAI 0
  • Target Price
  • TLSI $11.75
  • HCAI N/A
  • AVG Volume (30 Days)
  • TLSI 34.3K
  • HCAI 51.3K
  • Earning Date
  • TLSI 05-14-2025
  • HCAI 01-01-0001
  • Dividend Yield
  • TLSI N/A
  • HCAI N/A
  • EPS Growth
  • TLSI N/A
  • HCAI N/A
  • EPS
  • TLSI N/A
  • HCAI 0.11
  • Revenue
  • TLSI $29,431,000.00
  • HCAI $53,677,586.00
  • Revenue This Year
  • TLSI $56.00
  • HCAI N/A
  • Revenue Next Year
  • TLSI $52.17
  • HCAI N/A
  • P/E Ratio
  • TLSI N/A
  • HCAI $75.52
  • Revenue Growth
  • TLSI 58.99
  • HCAI 534.84
  • 52 Week Low
  • TLSI $3.50
  • HCAI $3.70
  • 52 Week High
  • TLSI $10.24
  • HCAI $10.97
  • Technical
  • Relative Strength Index (RSI)
  • TLSI 40.35
  • HCAI N/A
  • Support Level
  • TLSI $4.66
  • HCAI N/A
  • Resistance Level
  • TLSI $5.35
  • HCAI N/A
  • Average True Range (ATR)
  • TLSI 0.37
  • HCAI 0.00
  • MACD
  • TLSI -0.05
  • HCAI 0.00
  • Stochastic Oscillator
  • TLSI 43.44
  • HCAI 0.00

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares

Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider.

Share on Social Networks: